Performance of a Multiplex Serological Helicobacter pylori Assay on a Novel Microfluidic Assay Platform by Filomena, Angela et al.
HAL Id: hal-02322247
https://hal.archives-ouvertes.fr/hal-02322247
Submitted on 5 Nov 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Performance of a Multiplex Serological Helicobacter
pylori Assay on a Novel Microfluidic Assay Platform
Angela Filomena, Anna Guenther, Hannes Planatscher, Francois Topin,
Joseph She, Luca Formichella, Laurent Terradot, Markus Gerhard, Thomas
Joos, Hannelore Meyer, et al.
To cite this version:
Angela Filomena, Anna Guenther, Hannes Planatscher, Francois Topin, Joseph She, et al.. Perfor-
mance of a Multiplex Serological Helicobacter pylori Assay on a Novel Microfluidic Assay Platform.
Proteomes, MDPI, 2017, 5 (4), pp.24. ￿10.3390/proteomes5040024￿. ￿hal-02322247￿
proteomes
Article
Performance of a Multiplex Serological Helicobacter
pylori Assay on a Novel Microfluidic Assay Platform
Angela Filomena 1 ID , Anna Guenther 1, Hannes Planatscher 1, Francois Topin 2, Joseph She 2,
Luca Formichella 3, Laurent Terradot 4, Markus Gerhard 3, Thomas O. Joos 1, Hannelore Meyer 3
and Nicole Schneiderhan-Marra 1,*
1 NMI Natural and Medical Sciences Institute at the University of Tuebingen, Markwiesenstr 55,
72770 Reutlingen, Germany; angela.filomena@gmx.de (A.F.); anna.guenther@nmi.de (A.G.);
Planatscher@signatope.com (H.P.); Thomas.Joos@nmi.de (T.O.J.)
2 MyCartis, Technologiepark 4, 9052 Zwijnaarde, Belgium; ftopin@yahoo.fr (F.T.); jshe@mycartis.net (J.S.)
3 Institut für medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München,
Trogerstrasse 30, 81675 Munich, Germany; luca.formichella@gmx.de (L.F.); markus.gerhard@tum.de (M.G.);
hannelore.meyer@tum.de (H.M.)
4 UMR 5086 Molecular Microbiology and Structural Biochemistry, CNRS-Université de Lyon 1,
Institut de Biologie et Chimie des Protéines, 7 Passage du Vercors, 69367 Lyon CEDEX 07, France;
laurent.terradot@ibcp.fr
* Correspondence: nicole.schneiderhan@nmi.de; Tel.: +49-(0)7121-51530-815
Received: 29 August 2017; Accepted: 29 September 2017; Published: 3 October 2017
Abstract: Infection with Helicobacter pylori (H. pylori) occurs in 50% of the world population, and is
associated with the development of ulcer and gastric cancer. Serological diagnostic tests indicate an
H. pylori infection by detecting antibodies directed against H. pylori proteins. In addition to line blots,
multiplex assay platforms provide smart solutions for the simultaneous analysis of antibody responses
towards several H. pylori proteins. We used seven H. pylori proteins (FliD, gGT, GroEL, HpaA, CagA,
VacA, and HP0231) and an H. pylori lysate for the development of a multiplex serological assay on
a novel microfluidic platform. The reaction limited binding regime in the microfluidic channels
allows for a short incubation time of 35 min. The developed assay showed very high sensitivity
(99%) and specificity (100%). Besides sensitivity and specificity, the technical validation (intra-assay
CV = 3.7 ± 1.2% and inter-assay CV = 5.5 ± 1.2%) demonstrates that our assay is also a robust tool
for the analysis of the H. pylori-specific antibody response. The integration of the virulence factors
CagA and VacA allow for the assessment of the risk for gastric cancer development. The short assay
time and the performance of the platform shows the potential for implementation of such assays in a
clinical setting.
Keywords: Helicobacter pylori; microfluidic; multiplex serology; Evalution™; FliD
1. Introduction
Evalution™ (MyCartis, Zwijnaarde, Belgium) is a novel microfluidic assay platform, which allows
the multiplexing of up to 150 individual particle populations, combined with advantageous conditions
given by the microfluidic format and a short assay time [1]. Using different antigens immobilized on
individual particle populations makes multiplex serology possible.
Helicobacter pylori (H. pylori, HP) is a globally widespread Gram-negative bacterium with high
prevalence (70–90%) in developing countries and lower prevalence (25–50%) in developed countries [2].
Infection of the human stomach with H. pylori leads initially to an asymptomatic chronic gastric
inflammation, which can be followed by development of an atrophic gastritis and gastric cancer [2,3].
Therefore, H. pylori was declared as a type I carcinogen in 1994 [4]. Depending on the presence or
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absence of the virulence factor cytotoxin-associated gene A (CagA) and the vacuolating cytotoxin gene
A (VacA) alleles determining cytotoxicity [5], H. pylori strains can be classified into type I or type II
strains, whereof type I strains express the virulence factor CagA and produce the more cytotoxic variant
of VacA, while type II strains do not [6]. Infection with type I strains increases the risk for development
of gastric cancer [7]. The infection with H. pylori can be detected by invasive (via endoscopy and
biopsy) and non-invasive (stool antigen test (SAT), urea breath test (UBT), and serology) methods. SAT
and UBT have the advantage of indicating current, ongoing infection, but both tests are affected by
several parameters, such as colonization density, nutrition, other bacteria present in the gastrointestinal
tract, and co-medication, and thus, can produce false negative, as well as false positive results. Serology
is mostly independent of these confounding factors, but can usually not differentiate past from present
infection. However, due to the possibility of high throughput formats, serology can be used for
population-based screening approaches. Moreover, certain antibody responses have been correlated
with the presence of more severe gastric disease, and may thus have prognostic implications [8,9].
Thus, serologic assays which enable the analysis of multiple antibody responses in parallel from many
patients may serve as a valuable tool for population-based screening and risk assessment.
Here we present the development and technical validation of a multiplex serological H. pylori
assay using seven purified H. pylori proteins, a whole lysate of H. pylori, and three internal
controls. In addition to the virulence factors CagA and VacA, the flagellar hook-associated protein
2 homologue (FliD) has been described as a sensitive marker for immunodetection of H. pylori [10]. The
H. pylori gama-Glutamyltranspeptidase (gGT) is a virulence factor involved in immune evasion [11],
the chaperonin GroEL was described as a biomarker for gastric cancer [12], H. pylori adhesin A (HpaA)
is an adhesion protein involved in colonization [13], and the H. pylori oxidoreductase DsbK regulates
several bacterial virulence factors [14]. Some of these proteins had previously been employed in
serologic assays [9]. The assay was subsequently used to analyze serum samples of patients being
negative, positive, or eradicated for H. pylori infection. In addition, analysis of the serological response
of H. pylori positive patients to individual antigens was performed with regard to their disease state.
2. Materials and Methods
2.1. Technical Platform: Evalution™
All measurements were performed using the new microfluidic platform, Evalution™ (MyCartis,
Zwijnaarde, Belgium) as described previously [1]. The central components are the disc-shaped,
digitally encoded silicon microparticles, acting as a solid phase for immobilization of capture proteins
e.g., antibodies or antigens, and the microfluidic cartridges. Sixteen microscale channels are presented
on the cartridge to run up to 16 samples simultaneously or sequentially. Each channel can be loaded
with an independent microparticle population or with a mix of several populations coated with
different capture molecules. Both a real-time and end-point readout is feasible when imaging the
particles in bright field and fluorescence. Each microparticle generates a highly contrasted pixel
intensity; each pixel is a result, in total, there are approximately 1800 results per particle. For each
population, the arithmetic mean fluorescence intensity of at least 20 particles per population is
calculated and given as the population fluorescence (MFI).
Loading station, cartridges, different populations of microparticles, microparticle storage buffer
(MCPS), and loading buffer were provided by MyCartis.
2.2. Antigens and Human Sera
Seven affinity-purified H. pylori proteins (FliD (HP_0752), gGT (HP_1118), GroEL (HP_0010),
HpaA (HP_0797), CagA (HP_0547), VacA m1 (HP_0887), DsbK (HP_0231), were selected based on their
functional importance as H. pylori virulence factors [6,7] or their previously determined functionality
for serologic detection (unpublished data) of H. pylori infection. For CagA, the full-length sequence of
H. pylori strain P12 was used. This strain was isolated from a duodenal ulcer patient, and contains
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both the VacA cytotoxin and a functional cag pathogenicity island (cagPAI) [15,16]. The antigens, a
whole cell lysate of H. pylori strain 49,503 and three internal controls (human IgG as control for the
detection system, goat-anti-human IgG as a control for addition of sample, and E. coli lysate as a control
for unspecific binding) were immobilized as capture molecules to analyze the antibody response in
265 sera specimens. The Technical University of Munich (TUM) provided both recombinant antigens
and sera. The study cohort is described elsewhere [17], and included random consecutive volunteers
undergoing routine upper gastroscopy for gastrointestinal complaints between 2009 and 2012 in
Bayreuth, Germany. The diagnosis as positive, negative, or eradicated for a H. pylori infection was
determined by Warthin–Starry silver stain. An overview of the retrospective samples is given in
Table 1, including information about gender and age of the study population. The study was approved
by the ethics committee of the Technische Universität München (20 May 2009). Samples were only
used if all necessary clinical information was available and clearly defined.
Table 1. Overview of samples used in this study.
Gender Age
HP* Status n (Total)
Female Male
Female + Male Female Male
n % n %
negative 63 33 52.4 30 47.6 53.6 ± 13.3 53.8 ± 14.2 53.3 ± 12.2
positive (total) 139 73 52.5 66 47.5 55.1 ± 14.9 56.8 ± 15.4 53.2 ± 14.0
asymptomatic 66 34 51.5 32 48.5 55.2 ± 15.1 58.9 ± 14.6 53.0 ± 14.0
atrophy 18 11 61.1 7 38.9 55.1 ± 13.6 54.1 ± 13.0 56.7 ± 14.4
intestinal metaplasia 41 20 48.8 21 51.2 54.7 ± 13.7 57.6 ± 12.1 51.9 ± 14.5
ulcer 14 8 57.1 6 42.9 55.6 ± 18.3 56.4 ± 22.4 54.5 ± 10.7
eradicated 63 32 50.8 31 49.2 56.3 ± 13.5 57.4 ± 14.5 55.2 ± 12.4
* HP = H. pylori.
2.3. Antigen Immobilization
For the multiplex serological detection, a panel of eleven different microparticle populations
were coupled with the protein of interest. The immobilization was performed using the MyCartis
coupling protocol. Different coupling concentrations were tested and based on the height of the signal
intensities and coefficients of variation (CVs) the best coupling concentration was determined. Each
protein (120 µg) was coupled to a total number of 120,000 microparticles per population in a volume of
3.6 mL (except for CagA, 85 µg in 2.55 mL) using standard sulfo-NHS/EDC chemistry. Activation of
the particles was performed for 1 h with 3.6 mL of activation mix containing 10 mg/mL sulfo-NHS
and 50 mg/mL EDC in 100 mM MES + 0.25% (v/v) Tween 20 (pH 3.5). After activation, particles were
washed three times with coupling buffer (100 mM MES + 0.25% (v/v) Tween 20; pH 4.9). Proteins were
diluted in coupling buffer and incubated for 1 h with the activated particles. After immobilization,
excessive protein was washed off with wash buffer (10 mM PBS + 0.25% (v/v) Tween 20). Microparticles
were taken up in 3 mL storage buffer (MCPS, MyCartis), merged to a population mix, and aliquoted in
an expedient size for longer storage at −20 ◦C.
2.4. Generation of Quality Control Samples
Different sera were pooled to obtain three different quality control samples (QC1, QC2, and QC3),
which together cover low and medium/high ranges of reactivity for every antigen. For pool sample
or single serum sample preparation, sera were selected based on their responses towards the chosen
antigens using an in-house developed algorithm (based on [18]). The QC sample preparation was done
by using positive samples with different antibody responses towards the selected antigens. For QC1
five and for QC2, four sera were pooled in different volume rations. For QC3, a single serum was used,
which showed a suitable antibody response profile as a QC sample according to the used algorithm.
The final dilution of the QC samples was 1:100 in sample buffer (BRE + 10% E. coli lysate (v/v) + 0.25%
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Tween 20 (v/v); BRE = Blocking Reagent for ELISA, Roche Diagnostics GmbH, Mannheim, Germany).
Ready-to-use QC samples were aliquoted and stored at −80 ◦C. The quality control samples were
measured on each cartridge to ensure assay stability, both in screening and in validation.
2.5. Multiplex Assay Procedure
Serum samples and quality control samples were stored frozen in aliquots at −80 ◦C. Thawed
on ice, samples were vortexed and centrifuged at 4 ◦C and 3220g for 10 min. Subsequently, samples
were diluted 1:100 in sample buffer. For blocking unspecific bindings, a 20 min incubation at room
temperature was performed. Meanwhile, a cartridge was filled with the multiplexed population
mix using the loading station. A minimum of 20 microparticles per population was used for each
measurement. To avoid aggregation or lipid accumulation in channels, samples were filtered by
centrifugation for 3 min with 2500g at 4 ◦C in a filter plate (Pall GmbH, Dreieich, Germany, AcroPrep
96 0.2 µm, PN5042). After removing liquid from the inlet wells of the cartridge, a minimum of
80 µL filtrated sample was transferred to the wells, and microparticles were incubated for 30 min
with the sample under a constant flow by applying a differential pressure of 300 mbar between
inlet and outlet well. The inlet wells were emptied after incubation time, and filled with 100 µL
wash buffer and washed with constant flow for 1 min/300 mbar. Wells were emptied again and
filled with 50 µL of the detection antibody (goat-anti-human IgG (Fc) PE, Cat # 109 116 09, Jackson
Dianova, Hamburg, Germany) in a final concentration of 5 µg/mL diluted in BRE + 0.25% Tween 20.
After incubation of the detection antibody under constant flow for 5 min/300 mbar, again, a wash
step was performed. For the final imaging, the last liquid was removed, and the inlet wells were
filled with wash buffer. For the readout, each channel was scanned, and the particles were imaged
from the bottom of the cartridge in a bright field and fluorescence imaging mode. An evaluated
protocol of instrumental settings was used for all measurements: laser power 10 mW, temperature
25 ◦C/37 ◦C/37 ◦C (inlet wells/transit zone/detection zone), exposure time 100 ms, channel flush
pressure for reading was 50 mbar. Generated MFI values were exported as an excel file by the
Evalution™ Explore software (Version 1.6.6, MyCartis, Zwijnaarde, Belgium, 2015). Every sample had
its own sample specific background. MFI values of the antigen carrying microparticles of a sample
were corrected by subtracting the MFI value of the E. coli microparticle of the corresponding sample.
2.6. Intra- and Inter-Assay Precision
For the intra-assay precision, two positive and one negative sample were measured in 13 replicates
within one run, each sample on one cartridge. For the inter-assay precision, four cartridges with six
negative and six positive serum samples were measured on four different days by one operator.
Additionally, three quality control samples were measured on each validation cartridge. All results
were expressed as mean, standard deviation (SD), and as percentage coefficient of variation (% CV).
2.7. Cutoff Definition and Statistical Analysis
For the statistical analysis, an antigen-specific cutoff was calculated for each antigen. This included
the identification of outliers by using the interquartile range (IQR). Values were treated as outliers
if values were not between Q1 − 1.5 × IQR and Q3 + 1.5 × IQR. Outliers were excluded from the
cutoff calculations. For the calculations, data of 63 H. pylori negative sera were used. Except for FliD, a
cutoff for each antigen was defined as the mean MFI of negative sera + X × SD. The individual X for
an antigen was determined by best results for sensitivity and specificity at the lowest possible value
for X. The best result for the antigens gGT, GroEL, HpaA, CagA, and the H. pylori lysate, was defined
by the highest possible value of the sum of sensitivity and specificity. The best result for the antigens
VacA and HP0231 was defined by the highest possible specificity. Due to the problem that mean and
SD of FliD were zero, an arbitrary cutoff was chosen for FliD. Dividing the antigen-specific MFI value
of the samples by the antigen-specific cutoff yielded the signal-to-cutoff (S/CO) ratios. Antigens with
a S/CO ratio > 1 were considered to be reactive (positive).
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To perform statistical analysis, MFI or S/CO values were used in the software RStudio
(Version 3.2.16, RStudio Inc., Boston, MA, USA, 2015) and WEKA (Version 3.8.0, The University
of Waikato, Hamilton, New Zealand, 2016). Significant differences between two distributions were
shown using the Mann–Whitney U test. Odds ratios (ORs) and 95% confidence intervals (CI) were
determined, to quantify the association between two properties.
3. Results
3.1. Assay Development and Technical Assay Validation
The incubation times for the samples and the detection antibody were investigated during assay
development. Four different incubation times (10/20/30/40 min) were tested for four samples.
In Figure 1a,b the results for all H. pylori antigens of two exemplary samples are depicted. Saturation of
the signal was not reached for every antigen at the same time point. However, after 30 min of sample
incubation, a plateau was achieved for most antigens. To keep the assay as short as possible without
loss of sensitivity, 30 min was set as the final incubation time for samples. For examination of the
incubation time of the detection antibody, a kinetic for 11 min was performed with measurements at
every 30 s (see Figure 1c). Even if not all antigens showed the same MFI value, after 5 min of incubation
with the detection antibody, saturation was achieved for all antigens. Therefore, 5 min was set as the
final incubation time for the detection antibody.
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Figure 1. Investigation of the incubation times for the samples and the phycoerythrin labeled
anti-human IgG detection antibody. (a,b) Four different incubation times (10 min, 20 min, 30 min, and
40 min) were tested in four samples. Depicted are the MFI values of all used H. pylori antigens of
two samples. (c) Kinetic of incubation with the detection antibody for 11 min. A measurement was
performed approximately every 30 s.
After assay development, a technical validation was performed to demonstrate the precision of
the assay. Intra- and inter-assay precision of the multiplex serological H. pylori was assigned to a mean
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intra-assay precision of 3.7 ± 1.2% CV and a mean inter-assay precision of 5.5 ± 3.0% CV across all
eight antigens and all samples, thus indicating a stable test system.
3.2. Analysis of Clinical Samples
A total number of 265 serum samples from patients with defined clinical H. pylori status (see
Table 1) have been studied with the developed multiplex serological H. pylori assay. Patients had
either a negative, positive, or eradicated status for H. pylori infection. The antigens FliD, gGT, GroEL,
HpaA, and the H. pylori lysate were chosen for the classification of the H. pylori infection status. CagA
and VacA are of high diagnostic significance, as they have been shown to markedly increase the
risk for premalignant changes, gastric carcinoma, MALT lymphoma, and ulcers [19,20]. Antigens
of these two most important virulence factors were included, as well as the oxidoreductase HP0231.
The distribution of antibody reactivity towards the seven H. pylori antigens and one H. pylori whole
cell lysate is shown as boxplots in Figure 2. The reactivity of H. pylori negative and H. pylori positive
samples were significantly different for all antigens (see p values in Table 2). Also, the comparison of
H. pylori positive and H. pylori eradicated samples yielded only p values below the Bonferroni corrected
significance level (α′ = 1.25 × 10−3). When H. pylori negative and H. pylori eradicated samples were
compared, only VacA m1 and HP0231 provided p values above the significance level. By generation of
S/CO ratios, the specificity and sensitivity of every single antigen was calculated. All five antigens
for classification into HP negative or positive yielded a specificity >95%, and a sensitivity >82% (see
Table 2). The three antigens for patient stratification showed high specificity, but CagA and VacA m1
had a lower sensitivity for the assessment of the infection status compared to the five other antigens.
However, sensitivity of HP0231 was relatively high at 84.2%. Besides the H. pylori lysate with the best
overall performance in this study, FliD showed the best sensitivity (95.7%) as a single antigen. Using
a combined statistical analysis of the S/CO ratios of the four single antigens FliD, gGT, GroEL, and
HpaA, a sensitivity of 99.3% could be achieved. Figure 2 indicates that the serological response to the
selected antigens, especially FliD, HpaA, and H. pylori lysate, allow a relatively distinct separation of
the H. pylori eradicated samples from the H. pylori negative and H. pylori positive samples. Using the
five antigens for the classification of the infection status (FliD, gGT, GroEL, HpaA, and the H. pylori
whole lysate) in a random forest algorithm together with the H. pylori positive samples, 73% of the
H. pylori eradicated samples could be assigned correctly. However, when H. pylori negative, H. pylori
positive, and H. pylori eradicated samples were used in a random forest algorithm, only 57% of the
H. pylori eradicated samples could be classified correctly.
Table 2. Cutoff values, p values, specificity and sensitivity of every antigen in the multiplex
H. pylori assay.
p Values
Antigen Cutoff(MFI)
Negative vs.
Positive
Negative vs.
Eradicated
Positive vs.
Eradicated
Specificity
(%)
Sensitivity
(%)
infection
status
FliD 0.20 5.72 × 10−29 4.80 × 10−14 5.84 × 10−14 96.8 95.7
gGT 0.95 4.73 × 10−23 1.69 × 10−10 3.39 × 10−10 95.2 82.0
GroEL 2.76 2.02 × 10−24 3.58 × 10−7 5.99 × 10−17 96.8 87.1
HpaA 0.66 3.16 × 10−25 1.32 × 10−10 2.32 × 10−12 97.4 84.2
HP lysate 1.08 2.42 × 10−30 5.02 × 10−18 1.04 × 10−20 100.0 99.3
stratification
CagA 3.80 1.69 × 10−16 9.84 × 10−15 2.30 × 10−4 95.2 70.5
VacA m1 5.66 1.15 × 10−9 4.13 × 10−2 2.11 × 10−4 100.0 21.6
HP0231 2.86 2.21 × 10−11 1.39 × 10−2 2.69 × 10−6 98.4 84.2
For the significance testing between the investigated patient groups, a Mann–Whitney U Test was used. Except for
two values, all p values are below the Bonferroni corrected significance level α′ = 0.01 ÷ 8 antigens = 1.25 × 10−3.
The group of H. pylori positive samples contained subcategories of different disease state:
asymptomatic, atrophy (chronic atrophic gastritis), intestinal metaplasia, and ulcer. Atrophy or
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intestinal metaplasia status is considered to be a premalignant condition, bearing an increased risk for
gastric cancer development [21]. Antibody response to CagA, VacA m1, and HP0231 of the H. pylori
positive samples were examined in more detail. The S/CO distribution differs for the subgroups
(Figure 3); most of the groups showed very heterogeneous S/CO values, but the variance for CagA in
the intestinal metaplasia group was more distinct. ORs, as well as 95% Cis, were calculated for the
comparison of the different H. pylori positive subgroups (Table 3). The ORs of CagA (5.3) and VacA m1
(6.7) were significant in the comparison of the asymptomatic group with the atrophic group. In the
comparison of the asymptomatic group with the intestinal metaplasia group, an even higher OR of
CagA (6.0) was observed. In contrast, the OR of VacA m1 (1.7) decreased, and was not significant
anymore. By taking the atrophic group and the intestinal metaplasia group together to a group called
premalignant changes, CagA was still significant with an OR of 5.9 and a 95% CI of 2.2–15.4, but VacA
m1 was not significant. HP0231 showed sometimes ORs > 1, but they were not significant. ORs in the
comparison of the asymptomatic with the ulcer group were for CagA and VacA m1 greater than 1,
but also not significant.
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Table 3. Odds ratios and confidence intervals of different patient groups.
Risk Factor (n Patients)
Diseased not Diseased
Groups Antigen yes no yes no OR 95% CI
asymptomatic (n = 17) vs. atrophic
(n = 17)
CagA 14 3 8 9 5.3 1.1–25.2
VacA m1 8 9 2 15 6.7 1.2–38.6
HP0231 10 7 6 11 2.6 0.7–10.5
asymptomatic (n = 40) vs.
intestinal metaplasia (n = 40)
CagA 36 4 24 16 6.0 1.8–20.2
VacA m1 9 31 6 34 1.7 0.5–5.2
HP0231 14 26 19 21 0.6 0.2–1.5
asymptomatic (n = 51) vs.
premalignant changes (n = 57)
CagA 50 7 28 23 5.9 2.2–15.4
VacA m1 17 40 8 43 2.3 0.9–5.9
HP0231 24 33 24 27 0.8 0.4–1.8
asymptomatic (n = 14) vs. ulcer
(n = 14)
CagA 10 4 7 7 2.5 0.5–11.9
VacA m1 3 11 12 2 1.6 0.2–11.7
HP0231 5 9 7 7 0.6 0.1–2.5
The samples of the compared groups were matched for age and gender. The atrophic and intestinal metaplasia
status were taken together as “premalignant changes” and also compared to the asymptomatic group of samples.
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4. Discussion
During assay development, the incubation times for the samples and the detection antibody were
optimized in order to keep them as short as possible, without a loss of sensitivity. The microfluidic
system allows a short assay protocol, with a 35 min assay incubation time in total. This is less than
one third of the assay time needed in other commer ially available immunoblot systems. Besides
a high technical assay precision, very good results were achieved for specificity and sensitivity of
the selected antigens. The H. pylori lysate showed the best sensitivity (99.3%) and specificity (100%)
in this study, and the overall performance was better compared to other commercial tests (claimed
in the test manual), which also use a H. pylori lysate, e.g., anti-Helicobacter pylori IgG (Orgentec
Diagnostika GmbH, Main, Germany) or Helico Blot 2.1 (MP Biomedicals Asia Pacific Pte Ltd., the
Cavendish Singapore Science Park, Singapore). In comparison to another multiplex serological assay
by Michel et al. [22], which showed 89% sensitivity and 82% specificity, we received higher sensitivity
and specificity for FliD and the H. pylori lysate. The other antigens for sample classification used
in our assay yielded lower s nsitivity (82.0–87.1%) th n Michel et al. [22], but higher specificity
(95.2–97.4%). The clinical classificati n as positive or ne ative for an H. pylori infection of these samples
was determined by Warthin–Starry silver stain, after taking a biopsy, and not by serology. Therefore,
a comparison of sensitivity and specificity of our assay with a non-invasive clinical classification
method (e.g., ELISA) was not possible. However, sensitivity and specificity of the different H. pylori
antigens and the lysate in our assay should be confirmed with another set of samples positive and
negative for H. pylori.
FliD showed the best sensitivity (95.7%) as a single antigen, but also, 2 of 63 H. pylori negative
samples were reactive to FliD, giving the specificity of 96.8%. Exactly these two samples showed also
reactivity towards one other H. pylori antigen. Therefore, we suspect that these two H. pylori negative
patients had a former H. pylori infection, which was eradicated or lost a long time ago. The H. pylori
lysate is probably not sensitive enough to detect this low reactivity. However, a reduced sensitivity
for CagA and VacA m1 was expected due to the fact that these antigens are virulence factors, and not
expressed by each H. pylori strain [23].
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Although the seroresponses to FliD, HpaA, and H. pylori lysate allowed a relative distinct
separation of the H. pylori eradicated samples, classification using a random forest algorithm achieved
only 57% correctly classified H. pylori eradicated samples. The reasons, therefore, could be on the
one hand, the very diverse time points of H. pylori eradication (i.e., samples were taken between
1 and 17 years after eradication), and on the other hand, the individual decline of antibody titers
in the different patients, which is dependent on the antibody baseline before eradication [24,25].
The described study was not a prospective trial planned to analyze serum samples at a fixed time
point after eradication, but to analyze patient serum samples retrospectively from a cohort of patients
undergoing gastroscopy. As patient enrolment and sample acquisition is difficult, due to limited
patient numbers, exclusion of serum samples outside of a pre-selected time window after eradication
would have substantially diminished the number of analyzed samples below a critical threshold.
Using samples obtained before and after eradication of the same patient might allow for definition of a
decline rate, e.g., 25% [25], as an indicator of a successful eradication. However, antibodies directed
against CagA can be detected also for a very long time after H. pylori eradication [26,27], which we
confirmed in our findings: CagA seropositivity was the most frequently reactive (76.2%) in the samples
from eradicated individuals.
Our study on the subgroups of the H. pylori positive samples showed a strong correlation of gastric
pathologies (atrophy or intestinal metaplasia) with the seropositivity for CagA. VacA m1 seropositivity
was, in our study, more predictive for atrophic than for intestinal metaplasia samples, which was
also observed by Pan et al. [28]. Gwack et al. [29] analyzed H. pylori positive patients with or without
gastric cancer, and could observe, only for CagA, and not for VacA, a significant OR. We assume that
even if VacA seems to have a correlation with chronic atrophic gastritis, as seen in our study and by
Pan et al. [28] as well as by Gao et al. [30], there is no direct relation to gastric cancer [29], and only
CagA has relevance in estimations of the risk for developing gastric cancer. However, the received ORs
for CagA and VacA m1 in the atrophic group were in the same range as reported by Gao et al. [30],
but in contrast to Gao et al. [30], we could not observe significant ORs for the seroresponse to antigen
HP0231. Furthermore, CagA seropositivity could also be associated with ulcer (OR = 2.5) as observed
in our study, which is in accordance with previous studies [31,32], but the 95% CI did not show a
significance. However, it has to be mentioned that high variability of the S/CO values in the different
groups was observed, and due to small sample sets, 95% CIs were very broad.
In summary, we developed a multiplex serological H. pylori assay, which is a robust, specific, and
sensitive approach for the analysis of the H. pylori-specific antibody response. Through the integration
of the virulence factors CagA and VacA m1, it was possible to study the correlation with development
of gastric cancer. Seropositivity of CagA was associated with an approximately six times higher risk for
premalignant changes in comparison to H. pylori positive patients, without expression of the virulence
factor CagA (CagA seronegative patients). Therefore, it is possible to make estimations about the
risk for gastric cancer based on the CagA antibody reactivity of serum samples without the need of
a biopsy and long-lasting culturing of bacteria. Altogether, the Evalution™ platform is an excellent
technology for multiplex serological assay development, especially to keep incubation times as short
as possible, which we demonstrated with our developed multiplex H. pylori assay. The very short
assay time and the relatively small instrument would allow the implementation of the assay as a point
of care testing, and at the same time, allows the analysis of multiple samples in parallel.
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